GREATER COMBINED REDUCTIONS IN HBA1C ≥1.0% AND WEIGHT ≥5.0% WITH SEMAGLUTIDE VS COMPARATORS IN TYPE 2 DIABETES

Helena W. Rodbard,Srikanth Bellary,Irene Hramiak,Yutaka Seino,Robert Silver,Lars Holm Damgaard,Gurudutt Nayak,Jeppe Zacho,Vanita R. Aroda

GREATER COMBINED REDUCTIONS IN HBA1C ≥1.0% AND WEIGHT ≥5.0% WITH SEMAGLUTIDE VS COMPARATORS IN TYPE 2 DIABETES

2019

Helena W. Rodbard
Srikanth Bellary
Irene Hramiak
Yutaka Seino
Robert Silver
Lars Holm Damgaard
Gurudutt Nayak
Jeppe Zacho
Vanita R. Aroda

Abstract OBJECTIVE: Semaglutide is a glucagon-like peptide-1 (GLP-1) analog for the once-weekly treatment of type 2 diabetes (T2D). In the global SUSTAIN clinical trial program, semaglutide demonst...

Keywords:

Clinical trial
Obesity
Semaglutide
Type 2 diabetes
Endocrinology
Diabetes mellitus
Medicine
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations